Ozempic shortages are real, but are social media users to blame?

What did @abcnewsaus actually say?

The video follows Leonie, a 60-year-old Perth woman with type 2 diabetes who says she spent 12 months struggling to access Ozempic (semaglutide). She has since been diagnosed with peripheral neuropathy, a neurological condition affecting the nerves, and believes "the symptoms could have been prevented" if she had consistent access to the drug. The report frames celebrity-driven social media demand as the primary cause of Australia's Ozempic shortage, and a pharmacist interviewed argues that prescribers "are just not following the guidelines."

The broader argument is straightforward: people using Ozempic off-label for weight loss are crowding out patients who need it for blood sugar management, and that displacement is causing measurable harm. It is a legitimate news angle. The question is whether the specific medical claims hold up.

Does the science back this up?

On the shortage itself, yes, the data are real. On the neurological claim, it is more complicated than the video suggests.

Australia's Therapeutic Goods Administration (TGA) confirmed Ozempic shortages from mid-2022 onward, driven partly by off-label demand. The PBS figure cited in the video, roughly 275,000 patients accessing Ozempic by mid-2023, is consistent with publicly reported data. So the scale of the problem is accurately represented.

The peripheral neuropathy claim is where things get slippery. Peripheral neuropathy in type 2 diabetes is primarily caused by chronic hyperglycemia damaging small nerve fibers over time. Poor glycemic control is the dominant driver. Callaghan et al. (2012, Lancet Neurology) established that longstanding elevated blood glucose is the central mechanism. Whether interrupting semaglutide specifically, rather than any glycemic disruption, caused or accelerated Leonie's neuropathy is not something this video can establish. Semaglutide improves HbA1c, and better glucose control does reduce neuropathy risk, but the causal chain presented here is speculative without her full clinical history.

What did they get wrong (or right)?

They got the shortage narrative right, and they got the human cost framing right. Medication disruption in type 2 diabetes is genuinely dangerous, and that point deserves coverage.

What they got wrong, or at least oversimplified, is the neuropathy causation claim. The video implies Ozempic shortage directly caused peripheral neuropathy. That is not how diabetic neuropathy works. It develops over years of suboptimal glycemic control, not because one specific drug was unavailable for 12 months. If Leonie had other glycemic management options she could not access, or had chronically poor control before Ozempic, those factors matter enormously and go unmentioned.

The line "it's not actually meant for" weight loss is also imprecise. Semaglutide 2.4mg (Wegovy) is specifically approved for obesity management. Ozempic is the lower-dose formulation approved for type 2 diabetes. The drugs share an active ingredient but have different indications. Conflating them is a meaningful error that muddies the actual regulatory picture.

The pharmacist's complaint about prescribers not following guidelines is fair but the report correctly notes these are not enforceable regulations. Credit for including that caveat.

What should you actually know?

If you have type 2 diabetes and your GLP-1 medication supply is disrupted, the risk is real, but it is about blood glucose management overall, not about one drug specifically.

Several points are worth separating out. First, semaglutide is not the only medication that controls blood sugar in type 2 diabetes. Metformin, SGLT-2 inhibitors, and other GLP-1 agonists like dulaglutide (Trulicity) exist and may be accessible when Ozempic is not. A telehealth or in-person clinician can assess alternatives. Second, diabetic peripheral neuropathy is not reversible once established, but progression can be slowed with consistent glycemic control. The DCCT/EDIC trial (Nathan et al., 2005, NEJM) demonstrated that intensive glucose management reduces microvascular complications including neuropathy over the long term. Third, the TGA shortage is ongoing and the Pharmacy Guild's forecast of disruption into 2024 and beyond appears accurate based on global manufacturing constraints at Novo Nordisk. This is not purely a social media-demand story. It is also a supply chain story. Fourth, if you are using compounded semaglutide as an alternative, understand that compounded versions are not bioequivalent to branded Ozempic or Wegovy and have not undergone the same regulatory review. They are not interchangeable products.